• HOME
  • RESEARCH
    • Delta opiod receptors selective drugs for the treatments of alcohol use disorders
    • Biased signaling in neurological disorders
    • Delta-mu opioid receptor heteromers in chronic pain pathophysiology
    • Neuropharmacological effects of adolescent exposure to psychostimulants with or without alcohol
  • TECHNIQUES
  • PUBLICATIONS
  • LAB MEMBERS
    • Former Lab members
  • OUTREACH
    • Opioid and CNS depressant addiction and mental health disorders
    • Alcohol, psychostimulant and energy drink use and abuse
  • JOB OPPORTUNITIES
  • NEWS ARCHIVE
  • LAB PHOTOS
SEARCH

2022

Liu, LL, Van Rijn RM, Zheng W, Copper Modulates Adult Neurogenesis in the Subventricular Zone, Int J Mol Sci, 2022, 23(17), 9888:1-30

Blaine AT, Miao, Y, Yuan J, Palant S, Liu R, Zhang ZY, Van Rijn RM, Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions, Front Pharmacol. 2022, 13, 914651: 1-16

Meqbil YJ, van Rijn RM, challenges and opportunities for in silico drug discovery at delta opioid receptor. Pharmaceuticals, 2022, 15(7):873, 1-15, special issue “In Silico Approaches in Drug Design

Van Rijn RM and Spetea M, Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II, 2022, Molecules, 27(10) 3140:1-6

French AR, Gutridge AM, Yuan J, Royer QH, van Rijn RM, Sex and beta-arrestin-dependent effects of kappa opioid receptor mediated ethanol consumption in C57BL/6 mice, 2022 Pharmacology, Biochemistry and Behavior, 216, 173377 

French AR, van Rijn RM, An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects, 2022, Pharmacol Research, 177, 106091. IUPHAR themed issue - Biased G Protein Receptor Signalling

2021

Meqbil YJ, Su H, Cassell RJ, Mores KL, Gutridge AM, Cummins BR, Chen L, van Rijn RM, Identification of a novel delta opioid receptor agonist chemotype with potential negative allosteric modulator capabilities, 2021 Molecules, 26(23), 7236:1-15

Sharma K (1), Cassell R (1), Meqbil YJ (1), Su H, Blaine A, Cummins B, Mores K, Johnson D, Van Rijn RM, Altman R, Modulating beta-arrestin-2 recruitment at the delta and mu opioid receptor, RCS Med Chem, 2021, 12, 1958-67


Gutridge, AM (1), Chakraborty S (1), Varga BR (1), Rhoda ES, French AR, Blaine AT, Royer QH, Cui H, Yuan J, Cassell RJ, Szabó M, Majumdar S, van Rijn RM, Evaluation of kratom opioid derivatives as potential treatment option for alcohol use disorder, Frontiers in Pharmacology (Special issue The Pharmacology of Kratom and Its Alkaloids), 2021, 12:764885

Chakraborty S, Diberto J, Faouzi A, Bernhard SM, Gutridge AM, Ramsey S, Zhou Y, Provasi D, Nuthikattu N, Jilakia R, Nelson M, Asher W, Eans SO, Chintala S, Filizola M, van Rijn RM, Margolis EB, Roth B, Javitch J, McLaughlin JP, Che T, Majumdar S, A novel mitragynine analog displays low efficacy mu opioid agonism at Gi/o subtypes and antinociception with attenuated adverse effects, J Med Chem, 2021, 64(18): 13873-13892
​
Farrokh Sharifi F, Meqbil YJ, Otte A, Gutridge AM, Blaine AT, Van Rijn RM, Park K, Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose, Pharm Res, 2021, 38(7):1221-1234

Ganzen L, Ko MJ, Zhang M, Xie R, Chen L, Zhang L, James R, Mumm J, Van Rijn RM, Zhong W, Pang CP, Zhang M, Tsujikawa M, Leung YF, Drug Screening with Zebrafish behavior identifies Carvedilol as a potential treatment for Retinitis Pigmentosa, Scientific Reports, 2021, 11, 11432

Ko MJ, Chiang T, Mukadam AA, Mulia, GE, Gutridge AM, Lin A, Chester JA, Van Rijn RM, β-Arrestin–dependent ERK signaling reduces anxiety-like and conditioned fear–related behaviors in mice, Sci Signaling, 2021, 14(694), eaba0245  - Coverart

Van Rijn RM, Cushman MS, Lill M, Cassell RJ, Abdallah AHM, El-Sayed MSA, Delta opioid receptor agonist, US patent 10,954,224, issued March 23rd, 2021, application no. 62/518,633

Bertels Z, Witkowski W, Asif, S, Siegersma K, Van Rijn RM, Pradhan AA, A non-convulsant DOR agonist, KNT-127, reduces cortical spreading depression and nitroglycerin induced allodynia, Headache, 2021, 61(1):170-178

Creed SM (1), Gutridge AM (1), Argade MD, Hennessy MR, Brent Friesen JJB, Pauli GF, van Rijn RM, Riley AP, Isolation and Pharmacological Characterization of six Opioidergic Picralima nitida Alkaloids, J Natural Products, 2021, 84(1): 71-80
   - Akuammine is ACS molecule of the week

Ding Z, Knipp GT, Van Rijn RM, Chester JA, Watts VJ, The CUL3/neddylation inhibitor MLN4924 reduces inflammatory pain allodynia and ethanol-induced locomotor sensitization in mice, Behavioural Brain Research, 2021, 399, 113051:1-5
Picture
Cover art from Ko et al.
Depicting pERK in the dorsal hippocampus of a mouse brain following in vivo administration with the delta opioid agonist SNC80,

2020

Gutridge AM (1), Robins MT (1), Cassell RJ (1), Uprety R(1), Mores KL, Ko MJ, Pasternak G, Majumdar S, Van Rijn RM, Kratom reduces alcohol consumption in mice through a mechanism that relies on G protein-biased delta opioid receptor activation. Br J Pharmacol, 2020, 177(7): 1497-1513

Watts VJ, van Rijn RM, Flaherty DP, Kaur J, Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence, US patent 10,662,176, issued May 26th, 2020, application no. 16/038236

2019

Cassell RJ (1), Sharma KK (1), Su H, Cummins BR, Cui H, Mores KL, Altman RA, Van Rijn RM, The meta-position of Phe4 in Leu-enkephalin regulates potency, selectivity, functional activity, and signaling bias at the delta and mu opioid receptors, Molecules, 2019, 24, 4542: 1-15

Cai B, Kim D, Akhand S, Sun Y, Cassell RJ, Alpsoy A, Dykhuizen EC, Van Rijn RM, Wendt MK, Krusemark CJ, (2019), Selection of DNA-encoded Libraries to Protein Targets Within and On Living Cells. J Am Chem Soc, 141: 17057-17061


Watts VJ, van Rijn RM, Flaherty DP, Kaur J, Adenylyl cyclase inhibitors for chronic pain and opioid dependence, US patent 10,457,653, issued October 29th, 2019, application no. 16/564271

Mores KL (1), Cummins BR (1), Cassell RJ, Van Rijn RM, (2019) A review of the therapeutic potential of recently developed G protein-biased kappa agonists, Front Pharmacol, 10(407):1-14

Mores KL, Cassell RJ, Van Rijn RM, (2019) Arrestin recruitment and signaling by G protein-coupled receptor heteromers, Neuropharmacology​, 152:15-21 

Ko MJ (1), Mulia GE (1), Van Rijn RM (2019) Commonly used anesthesia/euthanasia methods for brain collection differentially impact MAPK activity in male and female C57BL/6 mice, Front Cell Neurosci, 13(96):1-10

Ko MJ, Van Rijn RM (2019) Response: Commentary: Commonly used anesthesia/euthanasia methods for brain collection differentially impact MAPK activity in male and female C57BL/6 mice, Front Cell Neurosci, 13(379):1-2

Robins MT, Blaine AT, Ha JE, Brewster AL, Van Rijn RM, (2019) Repeated use of the psychoactive substance ethylphenidate impacts neurochemistry and reward learning in adolescent male and female mice, Front Neurosci, 13 (124): 1-14

Ko MJ(1), Ganzen L (1), Coskun E, Mukadam AA, Lueng YF, Van Rijn RM, (2019) Critical evaluation of TRPA1-mediated locomotive behavior in zebrafish as a screening tool for novel anti-nociceptive drug discovery, Sci Rep, 9 (2430): 1-11

Cassell RJ (1), Mores KL (1), Zerfas BL, Mahmoud, AH, Lill MA, Trader TJ, Van Rijn RM, (2019) Rubiscolins at naturally occuring G protein-biased delta opioid receptor peptides, Eur Neuropsychopharmacol, 29 (3): 450-456


Kaur J, Soto-Velasquez M, Ding Z, Van Rijn RM, Watts VJ, Flaherty DP,  (2019) Optimization of a 1,3,4-oxadiazole series for inhibition of adenylyl cyclase 1 and 8 for the treatment of chronic pain, Eur J Med Chem, 162: 568-585 

2018

Alongkronrusmee D, Watts VJ, Van Rijn RM (2018), Bimolecular fluorescence complementation methodology to study G protein-coupled receptor dimerization in living cells, Neuromethods, 140, 205-​221

​Robins MT, Chiang T, Mores KL, Alongkronrusmee, D, Van Rijn RM, (2018) Critical role for Gi/o-protein activity in the dorsal striatum in the reduction of voluntary alcohol intake in C57BL/6 mice, Front. Psychiatry (special topic in opioid research), 9 (112):1-14 

Robins MT, Chiang T, Berry JN, Ko MJ, Ha JE, Van Rijn RM, (2018) Behavioral characterization of beta-arrestin1 knockout mice in anxiety-like and alcohol behaviors, Front. Behav. Neurosci, 12 (54):1-11

Marquez-Gomez R, Robins MT, Guitierrez-Rodelo C, Arias JM, Olivares-Reyes JA, Van Rijn RM, Arias-Montano JA, (2018) Functional histamine H3 and adenosine A2a receptors in recombinant cells and rat striatum, Pharmacol Res, 129:515-525

​
Alongkronrusmee D, Chiang T, Van Rijn RM (2018). Delta opioid pharmacology in relation to alcohol behaviors. Handb Exp Pharmacol, 247: 199-225

2017

​Burst TF, Alongkronrusmee D, Soto-Velasquez M, Baldwin TA, Ye Z, Dai M, Dessauer CW, van Rijn RM, Watts VJ (2017). Identification of a selective small molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci Signal, 10 (467)

Zeng L, Alongkronrusmee D, van Rijn RM (2017). An Integrated Perspective on Diabetic, Alcoholic, and Drug-Induced Neuropathy etiology and treatment in the United States. J Pain Res, 10: 219-228

2016

Anastasia AD, Selzer CC, Elentably H, Van Rijn RM, Krause JE (2016). Heroin use disoder - The evolving role of the pharmacist, Indiana Pharmacy Alliance continued education #5.

Alongkronrusmee D, Chiang T, Van Rijn RM (2016). Involvement of delta opioid receptors in alcohol withdrawal-induced mechanical allodynia in male C57Bl/6 mice. Drug and Alcohol Dependence, 167, 190-198

Yang S, Ben-Shalom R, Ahn M, Liptak AT, Van Rijn RM, Whistler JL, Bender KJ (2016). Beta-arrestin-dependent dopaminergic regulation of calcium channel activity in the axon initial segment. Cell Report, 16(6), 1518-1526
Robins MT, Lu J, Van Rijn RM (2016). Unique behavioral and neurochemical effects induced by repeated adolescent consumption of caffeine-mixed alcohol in C57BL/6 mice. PLOS ONE, 11(7):e0158189
Robins MT, DeFriel JN, Van Rijn RM (2016). Adolescent intake of caffeinated energy drinks does not affect adult alcohol consumption in C57BL/6 and BALB/c mice. Alcohol, 54, 1-9
Chiang T, Sansuk K, Van Rijn RM (2016). Beta-arrestin 2 dependence of delta opioid receptor agonists is correlated with alcohol intake. British Journal of Pharmacology, 173(2), 332-343

2013

Milan-Lobo L, Enquist J, van Rijn RM, Whistler JL (2013). Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLOS One, 8(3) e58362.  

van Rijn RM, Defriel JN, Whistler JL (2013). Pharmacological traits of delta opioid receptors: pitfalls or opportunities? Psychopharmacology (Berl), 228(1) 1-18. 

Harvey JH, van Rijn RM, Whistler JL (2013). A FLIPR assay for evaluating agonists and antagonists of GPCR heterodimers. Methods Mol Biol, 995 43-54.

van Rijn RM, Harvey JH, Brissett DI, DeFriel JN, Whistler JL (2013). Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. J Pharmacol Exp Ther, 344(1) 179-88.

2012

Brissett DI, Whistler JL, van Rijn RM (2012). Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes. Eur J Pain, 16(3) 327-37. 
 
van Rijn RM, Brissett DI, Whistler JL (2012). Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. Drug Alcohol Depend, 122(1-2) 156-9.  

van Rijn RM, Brissett, DI, Whistler JL (2012). Emergence of functional spinal delta opioid receptors after chronic ethanol exposure. Biol Psychiatry, 71(3) 232-8.  

2010

van Rijn RM, Brissett DI, Whistler JL (2010). Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther, 335(1) 133-9.
  
van Rijn RM, Whistler JL, Waldhoer M (2010). Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr Opin Pharmacol, 10(1) 73-9.  

2009

van Rijn RM, Whistler JL (2009). The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry, 66(8) 777-84. 

He L, Kim J, Ou C, McFadden W, van Rijn RM, Whistler JL (2009). Methadone antinociception is dependent on peripheral opioid receptors. J Pain, 10(4) 369-79

2008

van Rijn RM, Whistler JL (2008). The only way is up: preventing opioid tolerance by promoting cell surface expression of MOR-DOR heterodimers? Mol Interv, 8(6) 277-80.

Do not hesitate to contact us for electronic copies of published articles.
Proudly powered by Weebly